US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Immunic, Inc. - Common Stock
(NQ:
IMUX
)
7.410
+0.190 (+2.63%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunic, Inc. - Common Stock
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
November 11, 2024
Via
ACCESSWIRE
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
May 20, 2024
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20.
Via
TheNewswire.com
Immunic chief medical officer discusses promising treatments to mark World IBD Day
May 17, 2024
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19.
Via
TheNewswire.com
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
May 16, 2024
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease...
Via
TheNewswire.com
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
May 09, 2024
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,...
Via
TheNewswire.com
Topics
Intellectual Property
Immunic Inc set to bring relief with encouraging results
May 16, 2023
Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive.
Via
TheNewswire.com
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
May 01, 2024
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in...
Via
TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
March 21, 2024
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,...
Via
TheNewswire.com
Immunic CSO hails "great" progress with MS program
October 24, 2023
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some...
Via
TheNewswire.com
Immunic "super excited" about latest PMS trial data
October 11, 2023
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial...
Via
TheNewswire.com
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
August 21, 2023
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial...
Via
TheNewswire.com
Immunic CEO says Q2 results "couldn't be better"
August 07, 2023
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and...
Via
TheNewswire.com
Immunic Inc eyeing "big step" for multiple sclerosis patients
July 25, 2023
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS)...
Via
TheNewswire.com
Immunic IMU-856 trial data "clearly goes beyond" initial expectations
May 04, 2023
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at...
Via
TheNewswire.com
Immunic gets a "positive surprise" from lead asset trial
April 13, 2023
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838)...
Via
TheNewswire.com
Immunic Inc. (NASDAQ: IMUX) Featured in Virtual Coverage of the 34th Annual Roth Conference
March 11, 2022
Via
Investor Brand Network
